Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Sandra M. Axiak"'
Autor:
Sandra M. Axiak‐Bechtel, Stacey B. Leach, Jessica R. Newton‐Northup, Rowan J. Milner, Stacey A. Fox‐Alvarez, Lana I. Fagman, Kaylee A. Young, Deborah J. Tate, Zachary M. Wright, John D. Chretin, Justin W. Allen, Sean K. Yoshimoto, Kimberly A. Selting, Brian K. Flesner, Carrie R. White, Tracy Mills, Michael Aherne, Philip J. Bergman, LeAnn Qi, Kenneth A. Gruber, Michael F. Callahan
Publikováno v:
Journal of Veterinary Internal Medicine, Vol 37, Iss 6, Pp 2344-2355 (2023)
Abstract Background The melanocortin 4 antagonist TCMCB07 is safe and effective in reversing cachexia caused by sepsis or cancer in rodents. The safety and pharmacokinetics of TCMCB07 are demonstrated in healthy beagle dogs. Hypothesis/Objectives The
Externí odkaz:
https://doaj.org/article/15500eb735e64a8094068773cb02e744
Publikováno v:
Veterinary Medicine and Science, Vol 5, Iss 4, Pp 485-493 (2019)
Abstract Background Current advances in immunotherapy are an exciting area of study in canine osteosarcoma (OSA). The objective of this study was to determine the immune response in dogs with osteosarcoma by measuring stimulated leukocyte production
Externí odkaz:
https://doaj.org/article/51bd027e73e946eba41b3d1219e45a37
Autor:
Sandra M. Axiak‐Bechtel, Stacey B. Leach, David G. Scholten, Jessica R. Newton‐Northup, Brendan J. Johnson, H. E. Durham, Kenneth A. Gruber, Michael F. Callahan
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 3, Pp n/a-n/a (2021)
Abstract The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. D
Externí odkaz:
https://doaj.org/article/a92e2723027b41b2b1954a4acdd0347b
Autor:
Amy E. DeClue, Sandra M. Axiak-Bechtel, Yan Zhang, Saurabh Saha, Linping Zhang, David Tung, Jeffrey N. Bryan
Publikováno v:
Veterinary Research, Vol 49, Iss 1, Pp 1-11 (2018)
Abstract Clostridium novyi-NT (CVN-NT) spores germinate in hypoxic regions of tumors and have successfully cured induced neoplasia in mouse models and resulted in objective tumor responses in naturally developing neoplasia in the dog. The objective o
Externí odkaz:
https://doaj.org/article/f1780ef5e0394ba8b94880ae080c41fb
Autor:
Amy E. DeClue, Sandra M. Axiak-Bechtel, Yan Zhang, Saurabh Saha, Linping Zhang, David D. Tung, Jeffrey N. Bryan
Publikováno v:
BMC Veterinary Research, Vol 14, Iss 1, Pp 1-10 (2018)
Abstract Background Clostridium novyi-NT (CNV-NT), has shown promise as a bacterolytic therapy for solid tumors in mouse models and in dogs with naturally developing neoplasia. Factors that impact the immunologic response to therapy are largely unkno
Externí odkaz:
https://doaj.org/article/0afcf57f397b495bbf81c859c0eecd31
Autor:
David G Scholten, Michael F. Callahan, Kenneth A. Gruber, H E Durham, Jessica Newton-Northup, Stacey B. Leach, Brendan J. Johnson, Sandra M. Axiak-Bechtel
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 3, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives
The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were
Publikováno v:
Veterinary Medicine and Science
Veterinary Medicine and Science, Vol 5, Iss 4, Pp 485-493 (2019)
Veterinary Medicine and Science, Vol 5, Iss 4, Pp 485-493 (2019)
Background Current advances in immunotherapy are an exciting area of study in canine osteosarcoma (OSA). The objective of this study was to determine the immune response in dogs with osteosarcoma by measuring stimulated leukocyte production of tumor
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68114 (2013)
Fetal microchimerism has been suggested to play contradictory roles in women's health, with factors including age of the recipient, time elapsed since microchimerism occurred, and microchimeric cell type modulating disease. Both beneficial and harmfu
Externí odkaz:
https://doaj.org/article/3f8e99caf8594f868fc96072fd02ffb7
Autor:
Linping Zhang, Jeffrey N. Bryan, Saurabh Saha, Yan Zhang, Sandra M. Axiak-Bechtel, Amy E. DeClue, David Tung
Publikováno v:
BMC Veterinary Research, Vol 14, Iss 1, Pp 1-10 (2018)
BMC Veterinary Research
BMC Veterinary Research
Background Clostridium novyi-NT (CNV-NT), has shown promise as a bacterolytic therapy for solid tumors in mouse models and in dogs with naturally developing neoplasia. Factors that impact the immunologic response to therapy are largely unknown. The g
Autor:
D.A. Ruslander, Timothy M. Fan, R.S. Elmslie, Brenda Phillips, David M. Vail, G. S. Post, Mary K. Klein, Sandra M. Axiak-Bechtel, Douglas H. Thamm
Publikováno v:
Journal of Veterinary Internal Medicine
Background Standard of care treatment for multicentric lymphoma in dogs remains doxorubicin (DOX)-based combination chemotherapy, but owners may hesitate to commit the time and financial resources to complete such a protocol, typically requiring 12